Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors

Current Topics in Medicinal Chemistry

Volumn 4, Issue 10, 2004, Pages 1045-1057

  Tarby, Christine M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYCLOPROPYLETHYNYL 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 5 NITROIMIDAZOLE DERIVATIVE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ABACAVIR; ANTIRETROVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BENZONITRILE; BENZOPHENONE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; CALANOLIDE A; CAPRAVIRINE; DAPIVIRINE; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; EMTRICITABINE; ETRAVIRINE; INDAZOLE DERIVATIVE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; ERUCTATION; GENE MUTATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MEDICAL LITERATURE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; PATENT; REVIEW; SOMNOLENCE; TASTE DISORDER; TREATMENT FAILURE; VASCULITIS; VIRUS MUTANT;

ANTI-HIV AGENTS; CLINICAL TRIALS; COUMARINS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMIDAZOLES; MOLECULAR STRUCTURE; PATENTS; PYRANOCOUMARINS; PYRIDAZINES; PYRIMIDINES; QUINAZOLINES; REVERSE TRANSCRIPTASE INHIBITORS; SULFUR COMPOUNDS;

EID: 3042760870     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388295     Document Type: Review

References (79)

1. Smerdon, S.; Jager, J.; Wang, J.; Kohlstaedt, L.; Chirino, A.; Friedman, J.; Rice, P.; Steitz, T. Structure of the Binding Site for Nonnucleoside Inhibitors of the Reverse Transcriptase of Human Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. USA 1994, 91, 3911-3915.
2. Richman, D.; Havlir, D.; Corbeil, J.; Lonney, D.; Ignacio, C.; Spector, S.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti, D. Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected During Therapy. J. Virol. 1994, 68, 1660-1666.
3. Wei, X.; Ghosh, S.; Taylor, M.; Johnson, V.; Emini, E.; Deutsch, P.; Lifson, J.; Bonhoeffer, S.; Nowak, M.; Hahn, B.; Saag, M.; Shaw, G. Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection. Nature 1995, 373, 117-122.
4. Yeni, P.; Hammer, S.; Carpenter, C.; Cooper, D.; Fischl, M.; Gateil, J.; Gazzard, B.; Hirsch, M.; Jacobsen, D.; Katzenstein, D.; Montaner, J.; Richman, D.; Saag, M.; Schecter, M.; Schooley, R.; Thompson, M.; Vella, S.; Volberding, P. Antiretroviral Treatment for Adult HIV Infection in 2002 - Updated Recommendations of the International AIDS Society USA Panel. J. Am. Med. Assoc. 2002, 288, 222-235.
5. Gazzard, B. J. What are the Perceived Advantages and Disadvantages of Non-Nucleoside Reverse Transcriptase Inhibitors as First-line Therapy? HIV Medicine 2000, 1(S1), 11-14.
6. Dybul, M.; Chun, T.; Ward, D.; Hertogs, K.; Larder, B.; Fox, C.; Orenstein, J.; Baird, B.; Li, Y.; Green, L.; Engel, D.; Liu, S.; Mican, J.; Fauci, A. Evaluation of Lymph Node Virus Burden in Human Immunodeficiency Virus-infected Patients Receiving Efavirenz Based Protease Inhibitor Sparing Highly Active Antiretroviral Therapy. J. Infect. Dis. 2000, 181, 1273-1279.
7. Bacheler, L. Resistance to Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Drug Resistance Updates 1999, 2, 56-67.
8. Re, M.; Monari, P.; Bon, I.; Borderi, M.; Gibellin, D.; Schiavone, P.; Vitone, F.; Furlini, G.; La Placa, M. Patients Receiving a Combination of Stavudine, Lamivudine, and Efavirenz. Int. J. Antimicrob. Agents 2002, 20, 223-226.
9. Harrigan, P.; Larder, B. Extent of Cross-resistance Between Agents Used to Treat Human Immunodeficiency Virus Type 1 Infection in Clinically Dervied Isolates. Antimicrob. Agents Chemother. 2002, 46, 909-912.
10. Ruiz, N.; Nusrat, R.; Lauenroth-Mai, E.; Berger, D.; Walworth, C.; Bacheler, L.; Ploughman, L.; Tsang, P.; Labriola, D.; Echols, R.; Levy, R. Study DPC 083-203, a Phase II Comparison of 100 and 200 mg Once-Daily DPC 083 and 2 NRTIs in Patients Failing a NNRTI-containing Regimen. 8th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA.
11. Bacheler, L.; Anton, E.; Kudish, P.; Baker, D.; Bunville, J.; Krakowski, K.; Bolling, L.; Aujay, M.; Wang, X.; Ellis, D.; Becker, M; Lasut, A.; George, H.; Spalding, D.; Hollis, G.; Abremski, K. Antimicrob. Agents Chemother. 2000, 44, 2475-2484.
12. Bacheler, L.; Jeffrey, S.; Hanna, G.; D'Aquila, R.; Wallace, L.; Logue, K.; Cordova, B.; Hertogs, K.; Larder, B.; Buckery, R.; Baker, D.; Gallagher, K.; Scarnati, H.; Triton, R.; Rizzo, C. Genotypic Correlates of Phenotypic Resistance to Efavirenz in Viral Isolates from Patients Failing Nonnucleodie Reverse Transcriptase Inhibitor Therapy. J. Virol. 2001, 75, 4999-5008.
13. Quiros-Roldan, E.; Airoldi, M.; Moretti, F.; Fausti, C.; Pan, A.; Casari, S.; Torti, C.; Castelli, F.; Carosi, G. Genotype Resistance Profiles in Patients Failing an NNRTI-Containing Regimen, and Modifications After Stopping NNRTI Therapy. J. Clin. Lab. Anal. 2002, 16, 76-78.
14. Hanna, G.; Johnson, V.; Kuritzkes, D.; Richman, D.; Leigh Brown, A.; Savara, A.; Hazelwood, J.; D'Aquila, R. Patterns of Resistance Mutations Selected by Treatmnet of Human Immunodeficiency Virus Type 1 Infection with Zidovudine, Didanosine, and Nevirapine. J. Infect. Dis. 2000, 181, 904-911.
15. Deeks, S.G. Nonnucleoside Reverse Transcriptase Inhibitor Resistance. JAIDS J. Acquir. Immune Defic. Syndr. 2001, 26, S25-S33.
16. Buckheit, R. W., Jr. Non-Nucleoside Reverse Transcriptase Inhibitors: Perspectives on Novel Therapeutic Compounds and Strategies for the Treatment of HIV Infection. Expert Opin. Investig. Drugs 2001, 10, 1423-1442.
17. Moyle, G. The Emerging Roles of Non-Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Therapy. Drugs 2001, 61, 19-26.
18. De Clerq, E. New Developments in Anti-HIV Therapy. Farmaco 2001, 56, 3-12.
19. Corbett, J. W. A Review of Recent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Research Activity. Curr. Med. Chem.: Anti-Infective Agents 2002, 1, 119-140.
20. Pozniak, A. Why Switch from Protease Inhibitors (PI) to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)? HIV Medicine 2000, 1(S1), 7-10.
21. Hajós, G.; Riedl, Z.; Molnár, J.; Szabó, D. Nonnucleoside Reverse Transcriptase Inhibitors, Drugs Fut. 2000, 25, 47-62.
22. Högberg, M.; Morrison, I. HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Expert Opin. Ther. Patents 2000, 10, 1189-1199.
23. Fujiwara, T.; Sato, A.; El-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuna, Y. S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 1998, 42, 1340-1345.
24. Ren, J.; Nichols, C.; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; Stuart, D.I.; Stammers, D.K. Binding of the Second Generation Non-Nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding. J. Biol. Chem. 2000, 275, 14316-14320.
25. Hernandez, J.; Amador, L.; Amantea, M.; Chao, H.; Hawley, P.; Paradiso, L. Short-course Monotherapy with AG1549, a Novel Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), in Antiretroviral Naïve Patients. 7th Conference on Retroviruses and Opportunistic Infections, January 20-February 4, 2000, San Francisco, CA.
26. Wolfe, P.; Hawley, P.; Boccia, G.; Clendenin, N; Paradiso, L.; Shaw, T.; Chi-burris, K. Safety and Efficacy of Capravirine Versus Placebo in HIV-Infected Patient Failing a Non-Nucleoside Reverse Transcriptase Inhibitor Containing Regimen: Results of a Phase II, Double-blind, Placebo-controlled Study. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL.
27. Hawley, P.; Diniz-Piraino, S.; Paxton, W.; Pesano, R.; Chikami, G. Absence of Risk of Vasculitis in a HIV Population Taking Capravirine - Results of an Active Monitoring Plan. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain.
28. Corbett, J.; Ko, S.; Rodgers, J.; Jeffrey, S.; Bacheler, L.; Klabe, R.; Diamond, S.; Lai, C.; Rabel,S.; Saye, J.; Adams, S.; Trainor, G.; Anderson, P.; Erickson-Viitanen, S. Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus 1. Antimicrob. Agents. Chemother. 1999, 43, 2893-2897.
29. Corbett, J.; Ko, S.; Rodgers, J.; Gearhart, L.; Magnus, N.; Bacheler, L.; Diamond, S.; Jeffrey, S.; Klabe, R.; Cordova, B.; Garber, S.; Logue, K.; Trainor, G.; Anderson, P.; Erickson-Viitanen, S. Inhibiton of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 2000, 43, 2019-2030.
30. Corbett, J.; Rodgers, J. Discovery of Second Generation Quinazolinone Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1. Progress in Medicinal Chemistry, 2002, 40, 63-105.
31. Fiske, W.; Brennan, J.; Harrison, R.; Jobes, J.; Volpat, M.; Griffith, S. Pharmacokinetics of a Second-Generation NNRTI, DPC 083, after Multiple Oral Doses in Healthy Volunteers. 7th Conference on Retroviruses and Opportunistic Infections, January 20-February 4, 2000, San Francisco, CA.
32. Ruiz, N.; Nusrat, R.; Lazzarin, A.; Arasteh, K.; Goebel, F.; Audagnotto, S.; Rachlis, A.; Arribas, J.; Ploughman, L.; Fiske, W.; Labriola, D.; Levy, R.; Echols, R. Study DPC 083 201: A Phase II Doubl-blind (DB) Comparison of 3 Once Daily Doses of the NNRTI DPC 083 vs 600 mg Efavirennz (EFV) in Combination with 2 NRTIs in HIV Anti-retroviral Treatment-naïve Patients. 8th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA.
33. Ludovici, D. W.; Kukla, M. J.; Grous, P. G.; Krishnan, S.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; De Clerq, E.; Arnold, E.; Janssen, P. A. J. Evolutin of Anti-HIV Drug Candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to Imidoyl Thiourea (ITU). Bioorg. Med. Chem. Lett. 2001, 11, 2225-2228.
34. Ludovici, D. W.; Kavash, R. W.; Kukla, M. J.; Ho, C. Y.; Ye, H.; De Corte, B. L.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Moereels, H. E. L.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Lewi, P. J.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of Anti-HIV Drug Candidates. Part 2: Diaryltriazine (DATA) Analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2229-2234.
35. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R.W.; Andries, K.; de Bé thune, M. P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. Evolution of Anti-HIV Drug Candidates. Part 2: Diarylpyrimidine (DAPY) Analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
36. de Béthune, M.-P.; Azijn, H.; Andries, K.; Janssen, P.; Pauwels, R. In Vitro Selection Experiments Demonstrate Reduced Resistance with TMC120 and TMC125 Compared with First Generation NNRTIs. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois.
37. Grudzdev, B.; Horban, A.; Boron-Kaczmarska, A.; Gillé, D.; Van't Klooster, G.; Pauwels, R. TMC120, A New Non-Nucleoside Reverse Transcriptase Inhibitor, is a Potent Antiretroviral in Treatment Naïve, HIV-1 Infected Subjects. 8th Conference on Retroviruses and Opportunistic Infections, February 3-8, 2001, Chicago, IL.
38. Gruzdev, B.; Rakhmanova, A.; van't Klooster, G.; De Dier, K.; Comhaire, S.; Baede-Van Dijk, P.; de Béthune, M.-P.; Pauwels, R. One Week of Monotherapy with TMC125, a Novel Highly Potent NNRTI, Produces A Mean 2-Log Reduction in Viral Load in Antiretroviral-Naï ve, HIV-1 Infected Volunteers. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATH), October 27-31,2001, Athens, Greece.
39. Piscitelli, S.; Baede, P.; DeDier, K.; Van't Klooster, G.; Graham, N. Pharmacokinetics of TMC125 in HIV Infected Patients and Healthy Volunteers. 3rd International Workshop on Clinical Pharmaology of HIV Therapy, April 11-13, 2002, Washington, D. C.
40. Gazzard, B.; Pozniak, A.; Arasteh, K.; Staszewski, S.; Rozenbaum, W.; Yeni, P.; van't Klooster, G.; De Dier, K; Peeters, M; de Béthune, M.-P.; Graham, N.; Pauwels, R. TMC125, A Next-Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experience HIV-1-Infected Individuals with Phenotypic NNRTI Resistance. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, Washington.
41. Kashman, Y.; Gustafson, K.; Fuller, R.; Cardellina, J.; McMahon, J.; Currens, M.; Buckheit, R.; Hughes, S.; Cragg, G.; Boyd, M. The Calanolides, a Novel HIV-inhibitory Class of Coumarin Derivatives From the Tropical Rainforest Tree, Calophyllum Lanigerum. J. Med. Chem. 1992, 35, 2735-2743.
42. Currens, M.; Mariner, J.; McMahon, J.; Boyd, M. Kinetic Analysis of Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase by (+)-Calanolide A. J. Pharmacol. Exp. Ther. 1996, 279, 646-651.
43. Creagh, T.; Ruckle, J.; Tolbert, D.; Giltner, J.; Eiznhamer, D.; Dutta, B.; Flavin, M.; Xu, Z. Safety and Pharmacokinetics of Single Doses of (+)-Calanolide A, a Novel, Nautally Occurring Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy, Human Immunodeficiency Virus-Negative Human Subjects. Antimicrob. Agents Chemother. 2001, 45, 1379-1386.
44. Sherer, R.; Dutta, B.; Anderson, R.; Laudette-Aboulhab, J.; Kamarulzaman, A.; D'Amico, R.; Paton, N.; Abdullah, M.; Pollard, R.; Cooley, T.; Flavin, M.; Xu, Z. A Phase Ib Study of (+)-Calanolide A in HIV-1 Infected, Antiretroviral Therapy Naïve Patients. 7th Conference on Retroviruses and Opportunistic Infections, January 20-February 4, 2000, San Francisco, CA.
45. Baba, M; Shigeta, S; Yuasa, S; Takashima, H; Sekiya, K; Ubasawa, M; Tanaka, H; Miyasaka, T; Walker, R T; De Clercq, E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob.. Agents Chemother. 1994, 385, 688-692.
46. Corbett, J.; Gearheart, L.; Ko, S.; Rodgers, J.; Cordova, B.; Klabe, R.; Erickson-Viitanen, S. Novel 2,2-Dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as Non-nucleoside Reverse Transcriptase. Bioorg. Med. Chem. Lett. 2000, 10, 193-195.
47. Corbett, J.; Kresge, K.; Pan, S.; Cordova, B.; Klabe, R.; Rodgers, J.; Erickson-Viitanen, S. Trifluoromethyl-Containing 3-Alkoxymethyl- and 3-Aryloxymethyl-2-pyridones are Potent Inhibitors of HIV-1 Non-nucleoside Reverse Transcriptase. Bioorg. Med. Chem. Lett. 2001, 11, 309-312.
48. Byrnes, V.; Sardana, V.; Schleif, W.; Condra, J.; Waterbury, J.; Wolfgang, J.; Long, W.; Schneider, C.; Schlabach, A.; Wolanski, B.; Graham, D.; Gotlib, L.; Rhodes, A.; Titus, D.; Roth, E.; Blahy, O.; Quintero, J.; Staszewzki, S.; Emini, E. A Nonnucleoside Reverse Transcriptase Inhibitor Active on Human Immunodeficiency Virus Type 1 Isolates Resistant to Related Inhibitors. Antimicrob. Agents Chemother. 1993, 37, 1576-1579.
49. Coccuzza, A.; Chidester, D.; Cordova, B.; Klabe, R.; Jeffrey, S.; Diamond, S.; Weigelt, C.; Ko, S.; Bacheler, L.; Erickson-Viitanen, S.; Rodgers, J. 4,1-Benzoxazepine Analogues of Efavirenz (Sustive™ as HIV-1 Reverse Transcriptase Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1389-1392.
50. Corbett, J.; Pan, S.: Markwalder, J.; Cordova, B.; Klabe, R.; Garber, S.; Rodgers, J.; Erickson-Viitanen, S. 3, 3a-Dihydro[4,3,2-de]quinazolin- 2(1H)-ones are Potent Non-nucleoside Reverse Transcriptase Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 211-214.
51. Silvestri, R.; Artico, M.; Massa, S.; Marceddu, T.; De Montis, F.; La Colla, P. 1-[2-Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a Potent Lead for the Design of Novel NNRTIs. Bioorg. Med. Chem. Lett. 2000, 10, 253-256.
52. Silvestri, R.; Artico, M.; De Martino, G.; Ragno, R.; Massa, S.; Loddo, R.; Murfioni, C.; Loi, A.; La Colla, P.; Pani, A. Syntheisi, Biological Evaluation and Binding Mode of Novel 1-[2-(Diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles Targeted at the HIV-1 Reverse Transcriptase. J. Med. Chem. 2002, 45, 1567-1576.
53. Schafer, W.; Friebe, W.; Leinert, H.; Mertens, A; Poll, T.; von der Saal, W.; Zilch, H.; Nuber, B.; Ziegler, M. Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase: Molecular Modeling and X-ray Structure Investigations. J. Med. Chem. 1993, 36, 726-732.
54. Xu, G.; Loftus, T.; Wargo, H.; Turpin, J.; Buckeit, R.; Cushman, M. Solid-Phase Synthesis of the Alkenyldiarylmethane (ADAM) Series of Non-nucleoside Reverse Transcriptase Inhibitors. J. Org. Chem. 2001, 66, 5958-5964.
55. Xu, G.; Hartman, T.; Wargo, H.; Turpin, J.; Buckheit, R.; Cushman, M. Synthesis of Alkenyidiarylmethane (ADAM) Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors with Non-identical Aromatic Rings. Bioorg. Med. Chem. 2002, 10, 283-290.
56. Venkathachalam, T.; Sudbeck, E.; Mao, C.; Uckun, F. Anti-HIV Activity of Aromatic and Heterocyclic Thiazolyl Thiourea Compounds. Bioorg. Med. Chem. Lett. 2001, 11, 523-528.
57. Campiani, G.; Aiello, F.; Fabbrini, M.; Morelli, E.; Ramunno, A.; Armaroli, S.; Nacci, V; Garofalo, A.; Greco, G.; Novellino, E.; Maga, G.; Spadari, S.; Bergamini, A.; Ventura, L.; Bongiovanni, B.; Capozzi, M.; Bolacchi, F.; Marini, S.; Coletta, M.; Guiso, G.; Caccia, S. Quinoxalinylethylpyridylthioureas (QXPTs) as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Further SAR Studies and Identification of a Novel Orally Bioavailable Hydrazine-based Antiviral Agent. J. Med. Chem. 2001, 44, 305-315.
58. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M; Murgiono, C.; La Colla, P.; Loddo, R. Structure-based Design, Synthesis and Biological Evaluation of Conformationally Restricted Novel 2-Alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin- 4(3H)-ones as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. J. Med. Chem. 2001, 44, 2544-2554.
59. Barreca, M.; Chimirri, A.; De Luca, L; Monforte, A.; Monforte, P.; Rao, A.; Zappala, M.; Balzarini, J.; De Clerq, E.; Pannecouque, C.; Witvrouw, M. Discovery of 2,3-Diaryl-1,3-thizolidin-4-ones as Potent Anti-HIV-1 Agents. Bioorg. Med. Chem. Lett. 2001, 11, 1793-1796.
60. Barreca, M.; Balzarini, J.; Chimirri, A.; De Clercq, E.; De Luca, L; Holtje, H.; Holtje, M.; Monforte, A.; Monforte. P; Pannecouque, C.; Rao, A.; Zappala, M. Design, Synthesis, Structure-Activity Relationships, and Molecular Modeling Studies of 2,3-Diaryl-1,3-thiazolidin-4-ones as Potent Anti-HIV Agents. J. Med. Chem. 2002, 45, 5410-5413.
61. Rao, A.; Chimirri, A.; De Clercq; E.; Monforte, A.; Monforte, P.; Pannecouque, C.; Zappala, M. Synthesis and anti-HIV Activity of 1-(2,6 -Difluorophenyl)-1H,3H-Thiazolo[3,4-a]benzamidazole Structurally-related 1,2-Disubstituted Benzimidazoles. Farmaco 2002, 57, 819-823.
62. Chan, J.; Hong, J.; Hunter, R.; Orr, G.; Cowan, J.; Sherman, D.; Sparks, S.; Reitter, B.; Andrews, C.; Hazen, R.; St. Clair, M.; Boone, L.; Ferris, R.; Creech, K.; Roberts, G.; Short, S.; Weaver, K.; Ott, R.; Ren, J.; Hopkins, A.; Stuart, D.; Stammers, D. 2-Amino-6-arylsulfonylbenzonitriles as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1. J. Med. Chem. 2001, 44, 1866-1882.
63. Dymock, B.; Jones, P.; Merrett, J.; Parkes. K.; Parrratt, M.; Walter, D. Imidazole Derivatives for the Treatment of Viral Diseases. PCT Pat. Apl. WO02/42279, Nov. 12, 2001.
64. Dymock, B.; Jones, P.; Merrett, J.; Parkes. K.; Parrratt, M. Pyrazole Derivatives for the Treatment of Viral Diseases. PCT Pat. Apl. WO02/30907, Oct. 4, 2001.
65. Dymock, B.; Jones, P.; Merrett, J.; Parkes. K.; Parrratt, M. Pyrrole Derivatives for Treating AIDS. PCT Pat. Apl. WO02/025424, Apr. 30, 2001.
66. Corbau, R.; Mowbray, C.; Perros, M.; Stupple, P.; Wood, A. Pyrazole Derivatives. PCT Pat. Apl. WO02/04424, Jun. 21, 2001.
67. Uckun, F.; Venkatachalam, T. Phenoxy-Thiourea-Pyridine Compounds and Their Use for the Treatment of HIV Infections. PCT Pat. Apl. WO02/32873, Oct. 18, 2000.
68. Uckun, F.; Venkatachalam, T. Aromatic and Heterocyclic Thiazolyl Thiourea Compounds and Use. PCT Pat. Apl. W002/32889, Oct. 19, 2000.
69. Kukla, M.; Ludovici, D.; Kavash, R.; De Corte, B.; Heeres, J.; Janssen, P.; Koymans, L.; De Jonge, M.; Van Aken, K.; Krief, A. Prodrugs of HIV Replication Inhibiting Pyrimidines. PCT Pat. Apl. WO01/85699, May 3, 2001.
70. Kukla, M.; Ludovici, D.; Kavash, R.; De Corte, B.; Heeres, J.; Janssen, P.; Koymans, L.; De Jonge, M.; Van Aken, K.; Krief, A.; Leenders, R. HIV Replication Inhibitors. PCT Pat. Apl. WO01/85700, May 3, 2001.
71. Guillemont, J.; Benjahad, A.; Mabire, D.; N'guyen, C.; Grierson, D.; Monneret, C.; Bisangi, E.; Sanz, G.; Decrane, L. Pyridone and PyridineThione Derivatives Having HIV Inhibiting Properties. PCT Pat. Apt. WO02/24650, Sept. 18, 2001.
72. Simoneau, B. Non-nucleoside Reverse Transcriptase Inhibitors. PCT Pat. Apt. WO01/96338, Jun. 14, 2001.
73. Ogilvie, W.; Dezeil, R.; Naud, J.; O'Meara, J. Non-nucleoside Reverse Transcriptase Inhibitors. PCT Pat. Apl. WO02/07682, Mar. 21, 2002.
74. Yoon, S.; Lee, S.; Kim, N.; Park, Y.; Lee, G.; Kim, J.; Park, S.; Park, H.; Shin, D. Novel 3-Nitropyridine Derivatives and the Pharmaceutical Compositions Containing Said Derivatives. PCT Pat. Apl. WO01/38306, Nov. 27, 2000.
75. Yoon, S.; Lee, S.; Kim, N.; Park, Y.; Lee, G.; Kim, J.; Park, S.; Park, H.; Jang, H. Novel 5-Pyrimidinecarboxamide Derivatives and the Pharmaceutical Compositions Containing Said Derivatives. PCT Pat. Apl. WO01/38308, Nov. 27, 2000.
76. Andrews, C.; Chan, J.; Freeman, G.; Romines, K.; Tidwell, J. Benzophenones as Inhibitors of Reverse Transcriptase. PCT Pat. Apl. WO01/17982, Aug. 31, 2000.
77. Chan, J. Benzophenones as Inhibitors of Reverse Transcriptase. PCT Pat. Apl. WO02/07470, Sept. 12, 2002.
78. Rodgers, J.; Wang, H.; Patel, M.; Arvanitis, A.; Cocuzza, A. Tricyclic 2-Pyridone Compounds Useful as HIV Reverse Transcriptase Inhibitors. PCT Pat. Apl. WO02/08226, July 20, 2001.
79. Johnson, B.; Patel, M.; Rodgers, J.; Wang, H. Tricyclic Compounds Useful as HIV Reverse Transcriptase Inhibitors. PCT Pat. Apl. WO01/29037, Oct. 19, 2000.